TRANSGENE overview

Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer , today announced it has received approval from the French National Agency for the Safety of Medicines and Health Products (ANSM) to proceed with a Phase I/IIa study of the novel oncolytic Vaccinia virus BT-001. This announcement follows the approval received in December 2020 from the Belgian health authorities. The first patient is expected to be...

Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces the appointment of Gaëlle Stadtler as Director of Human Resources. Gaëlle is joining the Executive Committee and will directly report to Hedi Ben Brahim, Chairman and CEO of Transgene. Commenting on this appointment, Hedi Ben Brahim said: “ Given therapeutic innovation is a globally competitive endeavor, it is critical that Transgene...

Regulatory News: Under the liquidity contract between Transgene (Paris:TNG) and Natixis Oddo BHF SCA, on December 31, 2020, the resources provided for market making activities consisted of: - 195,000 Transgene Shares - € 277,892.83 For information, on June 30, 2020, the resources provided for market making activities consisted of: - 218,361 Transgene Shares - € 217,756.50 View source version on businesswire.com: https://www.businesswire.com/news/home/20210106005587/en/...

Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer , and BioInvent International AB (“BioInvent”) (OMXS: BINV) , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced they have received regulatory approval in Belgium for a clinical trial application (CTA) for a Phase 1/2a study of...

Regulatory News Transgene (Paris:TNG) today announced its financial reporting dates for 2021: March 10, 2021: 2020 Fiscal Year Results April 27, 2021: First Quarter 2021 Financial Results May 26, 2021: Annual Shareholders' Meeting September 22, 2021: First Half 2021 Financial Results November 4, 2021: Third Quarter 2021 Financial Results About Transgene Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer....

Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG) today announces that Management will participate in the upcoming investor events set out below. Transgene will meet institutional investors at the 10th Annual LifeSci Advisors Corporate Access Event (virtual event) from January 6th to 14th, 2021 in conjunction with the J.P. Morgan Healthcare conference . The Company will also attend: Oddo BHF Digital Forum : January 7 to 13, 2021 Biomed Event (virtual event): January 26 & 27, 2021 ***...

Regulatory News: Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, will present the Phase 1b/2 trial results of TG4001, a HPV16 targeted therapeutic vaccine, in combination with avelumab (BAVENCIO®), a human anti-PD-L1 antibody, in HPV16-positive recurrent and/or metastatic malignancies at ESMO Immuno-Oncology Virtual Congress 2020 , December 9-12, 2020. These data will be presented by the principal investigator, Professor...

Regulatory News: Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announced that the Board, at its meeting today, approved the appointment of Hedi Ben Brahim as the Company’s new Chairman and CEO, effective January 1 st , 2021. Hedi Ben Brahim, who has been a member of Transgene’s Board since May 2019, will replace Philippe Archinard. Philippe Archinard has led the company since 2005 and will remain a member of the Board of...

Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer , and BioInvent International AB (“BioInvent”) (OMXS: BINV) , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today present new data on BT-001, a novel oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4...

Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announced the presentation of the detailed results from the Phase 1b/2 trial combining TG4001, a HPV16-targeted therapeutic vaccine, with avelumab (BAVENCIO®), a human anti-PD-L1 antibody, in HPV16-positive recurrent and/or metastatic malignancies (NCT03260023) . The late-breaking e-poster is available and will be presented at the Society for...

Regulatory News: Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business update for the quarter ending September 30, 2020. Promising data for TG4001 to be presented at SITC 2020 A late breaking abstract presenting the detailed results from the Phase 1b/2 trial combining TG4001, a HPV16-targeted therapeutic vaccine, with avelumab in advance HPV16-positive has been accepted at the SITC 35th Anniversary...

Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that its Executive Vice President and Chief Scientific Officer, Eric Quéméneur, Pharm.D., PhD, will present today at the virtual 5 th Annual Neoantigen Based Therapies Summit. Presentation Title: Viral Immunotherapy Meets AI Technology Session: Clinical Translation - Utilizing Different Delivery Platforms to Enhance...

Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announced the detailed results from the Phase 1b/2 trial combining TG4001, a HPV16-targeted therapeutic vaccine, with avelumab (BAVENCIO®), a human anti-PD-L1 antibody, in HPV16-positive recurrent and/or metastatic malignancies. Following the unauthorized download of all abstracts on the SITC website, Transgene is communicating the...

Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announced that detailed results of the data from the Phase 1b/2 trial combining TG4001, a HPV16 targeted therapeutic vaccine, with avelumab (BAVENCIO®), a human anti-PD-L1 antibody, in HPV16-positive recurrent and/or metastatic malignancies, will be presented in a poster presentation at the upcoming virtual meeting of the Society for...

Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG ), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”) (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announce that they will be presenting a poster on BT-001 at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary...